Selecting patients for randomized trials: a systematic approach based on risk group

被引:21
作者
Vickers, Andrew J. [1 ]
Kramer, Barry S.
Baker, Stuart G.
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[2] NIH, Off Dis Prevent, Bethesda, MD 20892 USA
[3] NCI, Biometry Res Grp, Div Canc Prevent, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1186/1745-6215-7-30
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: A key aspect of randomized trial design is the choice of risk group. Some trials include patients from the entire at-risk population, others accrue only patients deemed to be at increased risk. We present a simple statistical approach for choosing between these approaches. The method is easily adapted to determine which of several competing definitions of high risk is optimal. Method: We treat eligibility criteria for a trial, such as a smoking history, as a prediction rule associated with a certain sensitivity ( the number of patients who have the event and who are classified as high risk divided by the total number patients who have an event) and specificity ( the number of patients who do not have an event and who do not meet criteria for high risk divided by the total number of patients who do not have an event). We then derive simple formulae to determine the proportion of patients receiving intervention, and the proportion who experience an event, where either all patients or only those at high risk are treated. We assume that the relative risk associated with intervention is the same over all choices of risk group. The proportion of events and interventions are combined using a net benefit approach and net benefit compared between strategies. Results: We applied our method to design a trial of adjuvant therapy after prostatectomy. We were able to demonstrate that treating a high risk group was superior to treating all patients; choose the optimal definition of high risk; test the robustness of our results by sensitivity analysis. Our results had a ready clinical interpretation that could immediately aid trial design. Conclusion: The choice of risk group in randomized trials is usually based on rather informal methods. Our simple method demonstrates that this decision can be informed by simple statistical analyses.
引用
收藏
页数:8
相关论文
共 9 条
[1]   Variations in lung cancer risk among smokers [J].
Bach, PB ;
Kattan, MW ;
Thornquist, MD ;
Kris, MG ;
Tate, RC ;
Barnett, MJ ;
Hsieh, LJ ;
Begg, CB .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (06) :470-478
[2]   CHOOSING SAMPLE SIZES TO MAXIMIZE EXPECTED HEALTH BENEFITS SUBJECT TO A CONSTRAINT ON TOTAL TRIAL COSTS [J].
BAKER, SG ;
HEIDENBERGER, K .
MEDICAL DECISION MAKING, 1989, 9 (01) :14-25
[3]   The fallacy of enrolling only high-risk subjects in cancer prevention trials: Is there a free lunch"?" [J].
Baker S.G. ;
Kramer B.S. ;
Corle D. .
BMC Medical Research Methodology, 4 (1)
[4]   Cancer risk prediction models: A workshop on development, evaluation, and application [J].
Freedman, AN ;
Seminara, D ;
Gail, MH ;
Hartge, P ;
Colditz, GA ;
Ballard-Barbash, R ;
Pfeiffer, RM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (10) :715-723
[5]   Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer:: Who benefits and by how much? [J].
Gill, S ;
Loprinzi, CL ;
Sargent, DJ ;
Thomé, SD ;
Alberts, SR ;
Haller, DG ;
Benedetti, J ;
Francini, G ;
Shepherd, LE ;
Seitz, JF ;
Labianca, R ;
Chen, W ;
Cha, SS ;
Heldebrant, MP ;
Goldberg, RM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1797-1806
[6]   The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial - Preface [J].
Gohagan, JK .
CONTROLLED CLINICAL TRIALS, 2000, 21 (06) :249S-250S
[7]   Calcium plus vitamin D supplementation and the risk of fractures [J].
Jackson, RD ;
LaCroix, AZ ;
Gass, M ;
Wallace, RB ;
Robbins, J ;
Lewis, CE ;
Bassford, T ;
Beresford, SAA ;
Black, HR ;
Blanchette, P ;
Bonds, DE ;
Brunner, RL ;
Brzyski, RG ;
Caan, B ;
Cauley, JA ;
Chlebowski, RT ;
Cummings, SR ;
Granek, I ;
Hays, J ;
Heiss, G ;
Hendrix, SL ;
Howard, BV ;
Hsia, J ;
Hubbell, FA ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, LH ;
Langer, RD ;
Lasser, NL ;
Limacher, MC ;
Ludlam, S ;
Manson, JE ;
Margolis, KL ;
McGowan, J ;
Ockene, JK ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Sarto, GE ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Whitlock, E ;
Anderson, GL ;
Assaf, AR ;
Barad, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07) :669-683
[8]   When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment [J].
Sinclair, JC ;
Cook, RJ ;
Guyatt, GH ;
Pauker, SG ;
Cook, DJ .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (03) :253-262
[9]   Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy [J].
Stephenson, AJ ;
Scardino, PT ;
Eastham, JA ;
Bianco, FJ ;
Dotan, ZA ;
DiBlasio, CJ ;
Reuther, A ;
Klein, EA ;
Kattan, MW .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :7005-7012